Sign up


Match Document Document Title
8987224 MicroRNA-198 as a tumor suppressor in pancreatic cancer  
A novel network of tumorigenic prognostic factors is identified that plays a critical role in advanced pancreatic cancer (PC) pathogenesis. This interactome is interconnected through a central...
8987226 Modified single-stranded polynucleotides  
It is intended to provide a polynucleotide that is resistant to RNase and has an RNA interference effect, etc. The present invention provides a single-stranded polynucleotide that is derived from a...
8987223 Treatment of pulmonary and pleural fibrosis using HSP27 inhibitors  
Reduction of HSP27 expression is in beneficial in the treatment of pleural and pulmonary fibrosis and in particular subpleural fibrosis and IPF. Pharmaceutical compositions for this purpose contain...
8987215 Composition for use in gene therapy  
A composition useful in gene therapy and a method of treatment to effect gene therapy is provided. In particular, a pharmaceutical composition comprising a nonimmunogenic net polyanionic...
8987227 Hepatitis C dsRNA effector molecules, expression constructs, compositions, and methods of use  
The present invention provides agents, compositions, constructs and methods for silencing HCV polynucleotides, as well as methods and compositions for treating or preventing HCV infection in a...
8980858 Treatment of methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA  
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Methionine Sulfoxide Reductase A (MSRA), in particular, by targeting natural antisense...
8980860 Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG  
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Discs large homolog (DLG), in particular, by targeting natural antisense...
8980856 Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3  
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Colony-stimulating factor 3 (CSF3), in particular, by targeting natural antisense...
8980855 Minor groove binder (MGB)-oligonucleotide miRNA antagonists  
Compositions and methods for inhibiting the actions of non-coding RNAs such as miRNAs and piRNAs are provided. The compositions comprise single or double stranded oligonucleotides conjugated with...
8980853 Compositions and methods for modulation of SMN2 splicing in a subject  
Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a...
8980857 Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4  
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of PAR4, in particular, by targeting natural antisense polynucleotides of PAR4. The...
8980861 Method for determining activators of excitatory synapse formation  
The invention provides methods of screening a compound that can increase spine/excitatory synapse formation and/or numbers. The compound is identified by contacting Ephexin5 with a test compound...
8975079 Reducible polymers for nonviral gene delivery  
Provided herein are biodegradable copolymers and nanoplex delivery systems comprising the same and a cargo molecule, such as a nucleic acid, a polynucleotide or other biomolecule. The biodegradable...
8969317 MicroRNA compounds and methods for modulating miR-21 activity  
Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity....
8969316 Compounds and methods for modulating expression of DGAT2  
The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense...
8969318 Bispecific aptamers mediating tumour cell lysis  
Disclosed are bispecific aptamers binding with high specifity to a tumour specific antigen (TSA) and a effector cell specific antigen (ESA) for treatment of cancer.
8969314 Methods for use in modulating miR-122a  
Methods are provided for the treatment of cardiovascular or metabolic diseases characterized by elevated serum total cholesterol, elevated serum LDL-cholesterol, or elevated serum triglycerides,...
8962585 Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63  
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Protein 63 (p63), in particular, by targeting natural antisense polynucleotides...
8962592 Methods of treating a meiotic kinesin associated disease  
The invention provides methods of treating a meiotic kinase-associated disease, preferably the meiotic kinase HSET, by administering an inhibitor of the meiotic kinase. Preferably, the disease is...
8962584 Compositions for controlling Varroa mites in bees  
An isolated nucleic acid agent is disclosed comprising a nucleic acid sequence which downregulates expression of a gene product of a Varroa destructor mite. Compositions comprising same and uses...
8962588 Micro-RNAS that control myosin expression and myofiber identity  
The present invention relates to the identification of two microRNAs, miR-499 and miR-208b, that repress fast skeletal muscle contractile protein genes. Expression of miR-499 and/or miR-208b can be...
8962586 Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1  
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Pyrroline-5-carboxylate reductase 1 (PYCR1), in particular, by targeting natural...
8962582 PKR activation via hybridization chain reaction  
The present application relates to the use of hybridization chain reaction (HCR) to form double stranded RNA polymers in the presence of a target, such as a nucleic acid associated with a disease...
8962757 Graft polymers for enhanced intracellular delivery of antisense molecules  
Innovative graft polymers designed for the efficient delivery of antisense molecules into biological cells and for maintaining the biological activity of these molecules while in serum and other...
8957037 Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor  
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Reprogramming factor, in particular, by targeting natural antisense polynucleotides...
8957012 Gamma secretase inhibitor for treatment of herpesvirus infection  
This invention relates to methods and compositions for the treatment of malignancies associated with gamma-herpesvirus infection. Specifically, the invention relates to the use of gamma-secretase...
8957039 Methods and compositions for the diagnosis and prognosis of cervical intraepithelial neoplasia and cervical cancer  
The invention provides methods and compositions for the diagnosis and prognosis of cervical intraepithelial neoplasia and cervical cancer. The methods comprise the step of determining the...
8957041 Short interfering ribonucleic acid (siRNA) for oral administration  
Short interfering ribonucleic acid (siRNA) for oral administration, said siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each...
8957040 Selective reduction of allelic variants  
Disclosed herein are antisense compounds and methods for selectively of reducing expression of an allelic variant of a gene containing a single nucleotide polymorphism (SNP). Such methods,...
8957191 Nucleic acid comprising zwitterionic nucleotides  
This invention provides pH-responsive zwitterionic nucleotides and nucleic acids comprising said nucleotides, wherein said zwitterions are constituted from one or more anionic internucleoside...
8957038 Treatment of neurological disorders  
This invention provides treatment compositions as well as systems and methods of determining and administering an effective amount of treatment for a neurological disorder. The treatment...
8957199 Oligoribonucleotide or peptide nucleic acid capable of inhibiting activity of hepatitis C virus  
The present inventors focused on siE sequences that have been thought to show RNAi activity against HCV viral RNAs, and mainly selected the D5-50 and D5-197 regions present within the IRES region,...
8951979 Pain treatment using ERK2 inhibitors  
This application describes methods and compositions for reducing, inhibiting and/or treating pain that involve use of ERK2 inhibitors.
8951984 Oligonucleotides for modulation of target RNA activity  
The present invention relates to oligonucleotides for modulation of target RNA activity. Thus, the invention provides oligonucleotides that bind to microRNA binding sites of target RNA. The...
8951527 Radioprotectants targeting thrombospondin-1 and CD47  
Described herein is the discovery that cell and tissue survival can be dramatically increased following radiation exposure through inhibition of the interaction between TSP-1 and CD47. This effect...
8951982 Methods and compositions for the treatment of eye disorders with increased intraocular pressure  
The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules...
8951981 Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1  
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Paraoxonase 1(PON1), in particular, by targeting natural antisense polynucleotides of...
8946185 Agent for suppressing expression of dominant allele  
An agent for selectively suppressing the expression of a dominant allele while allowing expression of wild-type or desired alleles and methods for using the agent are described. The RNAi agent has...
8946170 Sustained release siRNA for ocular drug delivery  
An ocular implant comprising siRNA complexed with a transfection agent selected from the group consisting of cationic lipids and short cell penetration peptides, wherein the complex is associated...
8946181 Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8  
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Interferon Regulatory Factor 8 (IRF8), in particular, by targeting natural antisense...
8946186 QSOX1 as an anti-neoplastic drug target  
The present invention provides methods for tumor treatment by administering an inhibitor of quiescin sulfhydryl oxidase 1 (QSOX1), compositions comprising such inhibitors, and methods for...
8946177 Methods and compositions involving miRNA and miRNA inhibitor molecules  
The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns...
8946184 Aptamer therapeutics useful in the treatment of complement-related disorders  
The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
8946180 Means and methods for the specific modulation of target genes in the CNS and the eye and methods for their identification  
Provided are methods for the treatment of disorders of the central nervous system (CNS) and the eye. In particular, use of compositions comprising a compound capable of modulating a target gene or...
8946182 Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1  
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of RNase H1, in particular, by targeting natural antisense polynucleotides of RNase H1....
8946179 Oligomeric compounds and compositions for use in modulation of small non-coding RNAs  
Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding...
8946176 Compositions and methods for inhibiting expression of RRM2 genes  
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a RRM2 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or...
8946178 Compositions and methods for treatment of pouchitis  
The present invention relates methods of treating pouchitis by administering a pharmaceutical formulation suitable for rectal use, such as an enema or suppository, comprising an antisense...
8940712 Micro-RNA family that modulates fibrosis and uses thereof  
The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29...
8940683 Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors  
The present invention is drawn to methods and compositions for treating inflammatory disorders of the lower airways, comprising administering an effective amount of an agent, which modulates the...